Atogepant clinical trials
Atogepant is named as an intervention in 8 current clinical trials in our Italy, UK, Poland, Japan, USA, Spain, Netherlands, Denmark, Canada, France, Belgium, Sweden, Israel, Portugal, South Korea, China, Germany, Czechia, Taiwan and Switzerland registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AbbVie (5). The most-studied condition is Episodic Migraine.
Where Atogepant is approved
All regulators →Of the three regulators tracked here, the first to approve Atogepant was the US, on 28 Sep 2021. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Atogepant patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Atogepant, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 9 listed patents; the last listed expires 27 Feb 2043 (US 12350259).
- Latest patent on the drug substance itself: 28 Sep 2035 (US 8754096).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Atogepant
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Atogepant works
All drug targets →- Calcitonin gene-related peptide type 1 receptor antagonist AntagonistTarget: CALCRL calcitonin receptor like receptor✓ In ChEMBL and the Guide to Pharmacology
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3991065, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9730, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Atogepant
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 2 technology appraisals of Atogepant. 2 are current, and 2 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Atogepant for treating migraine NICE TA1172 | Optimised | 30 Jun 2026 | Current |
| Atogepant for preventing migraine NICE TA973 | Optimised | 15 May 2024 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Atogepant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: AquiptaEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Atogepant
- ChEMBL
- CHEMBL3991065
- DrugBank
- DB16098
- PubChem CID
- 72163100
- CAS number
- 1374248-81-3
- FDA UNII
- 7CRV8RR151
- Wikidata
- Q76797798
- Wikipedia
- Atogepant
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Atogepant
8 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Atogepant across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Atogepant on the HPRA medicines list.
- AQUIPTA 10 mg tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/23/1750/001-002
- AQUIPTA 60 mg tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/23/1750/003-004
Supply shortages
No entry for Atogepant in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Atogepant
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 5 |
| IRCCS National Neurological Institute "C. Mondino" Foundation | 1 |
| University of Florence | 1 |
| Konrad Peter Weber | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Atogepant trials
How many clinical trials are testing Atogepant?
8 current trials in our Italy, UK, Poland, Japan, USA, Spain, Netherlands, Denmark, Canada, France, Belgium, Sweden, Israel, Portugal, South Korea, China, Germany, Czechia, Taiwan and Switzerland registers name Atogepant (also registered as AGN-241689) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Atogepant trials recruiting patients?
Yes. 4 of the 8 trials are recruiting: 3 with sites in Italy, 2 with sites in UK, 2 with sites in Poland, 2 with sites in Japan, 2 with sites in USA, 1 with sites in Spain, 2 with sites in Netherlands, 2 with sites in Denmark, 2 with sites in Canada, 1 with sites in France, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Israel, 1 with sites in Portugal and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Atogepant clinical trials?
AbbVie (5), IRCCS National Neurological Institute "C. Mondino" Foundation (1), University of Florence (1) and Konrad Peter Weber (1). The number in brackets is how many trials each organisation leads.
Is Atogepant licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Atogepant, for example AQUIPTA 10 mg tablets (AbbVie Deutschland GmbH & Co. KG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Atogepant shortage?
Not in the lists we track: Atogepant has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Atogepant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Atogepant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Atogepant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.